Risk factors

Omnicell added new risk disclosures around 2025 tariffs, customer lease financing, and cash concentration limits. Disclosures were updated to reference the new Titan XT cabinet and DOJ data security rules.

Swiss continuation shifts shareholder rights, governance, dispute forums, dividend approvals, and share-repurchase flexibility.

The company added risks regarding new U.S. tariffs and specific supervisory control and data acquisition system vulnerabilities at client facilities. Credit facility terms were updated to reflect the new 2025 Credit Facility.

Opko highlights evolving risks around FCPA compliance and the commercialization of NGENLA following FDA approval.

Oppenheimer added new risk disclosures regarding potential 24/7 market trading structures, digital asset custody gaps, and climate change reporting. Dividend payout disclosures updated from $0.66 to $1.72 per share for 2025. Leadership references adjusted regarding CEO and Chairman roles for Mr. Albert Lowenthal.

Geological and technology risks now cover conventional geothermal, battery storage, and emerging EGS projects.

Organogenesis highlights new FDA regulatory risks for human cell and tissue products like Affinity, Novachor, and NuShield.

Insurance subsidiary dividend restrictions and holding company liquidity are highlighted through new disclosures and reworded sections.

Merger-specific risks were removed, while expanded nationwide retail lending creates new consumer-law and tax compliance exposure.

OneSpan faces growth challenges as hardware Digipass revenue declines, offset by expanding software and digital agreements.

Total indebtedness increased to approximately $2.6 billion, with term loan balances rising to $500.0 million as of December 31, 2025.

PAR Technology updated its risk factors to emphasize investments in AI-native products, adjust share dilution impacts, and reflect prior-year operating losses through fiscal 2025.